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ABSTRACT
Gene expression profiles of human ameloblastoma 
microdissected cells were characterized with the 
purpose of identifying genes and their protein 
products that could be targeted as diagnostic and 
prognostic markers as well as for potential thera-
peutic interventions. Five formalin-fixed, decalci-
fied, paraffin-embedded samples of ameloblastoma 
were subjected to laser capture microdissection, 
linear mRNA amplification, and hybridization to 
oligonucleotide human 41,000 RNA arrays and 
compared with universal human reference RNA, 
to determine the gene expression signature. 
Assessment of the data by Significance Analysis of 
Microarrays (SAM) and cluster analysis showed 
that 38 genes were highly expressed (two-fold 
increase) in all samples, while 41 genes were 
underexpressed (two-fold reduction). Elements of 
the sonic hedgehog pathway and Wingless type 
MMTV integration site family were validated by 
immunohistochemistry. We have identified the 
expression of multiple genes and protein products 
that could serve as potential diagnostic, prognos-
tic, and therapeutic targets.
KEY WORDS: ameloblastoma, gene expression 
profile, human, microarray.
InTRODuCTIOn
Ameloblastoma is an aggressive tumor of odontogenic epithelial origin, with devastating morbidity if left untreated, due to its unlimited growth 
potential. It is characterized by a high rate of recurrence (up to 70%, depend-
ing on the treatment modality) and potential to undergo malignant transfor-
mation and to metastasize (up to 2% of cases). Malignant ameloblastoma is 
defined as a histologically benign-appearing ameloblastoma with metastasis 
(Goldenberg et al., 2004; Cardoso et al., 2009). Surgical resection is the treat-
ment of choice, which can cause further morbidity to the craniofacial com-
plex, with loss of function and esthetics (Olasoji and Enwere, 2003).
Gene expression profiling of tumor cell populations has advanced our 
understanding of the pathogenesis of human tumors (Naderi et al., 2004). The 
identification of specific genes or groups of genes that are deregulated, and 
thus potentially playing a role in initiation, proliferation, and morphological 
determination of the tumor, could provide new diagnostic and therapeutic 
approaches. Laser capture microdissection (LCM) allows for the isolation of 
single cells, with no detrimental effect on PCR amplification, and can be 
coupled to high-density oligonucleotide arrays to obtain expression profiles 
from cell populations of complex tumors (Luzzi et al., 2003).
Knowledge of early events leading to and promoting tumorigenesis in 
ameloblastoma, and odontogenic tumors in general, remains limited, partly 
because studies directed at identifying molecular factors and events that initi-
ate and drive tumorigenesis are inconclusive. There have been two microarray 
studies of ameloblastoma (Heikinheimo et al., 2002; Carinci et al., 2004), one 
of them using cDNA microarrays containing 19,000 human cDNAs, and, 
more recently, an oligonucleotide analysis of whole-tissue ameloblastoma in 
a 34,000 human RNA microarray (Lim et al., 2006). The objectives of our 
study were: (a) to characterize the gene expression profile of laser-captured 
microdissected ameloblastoma cells using oligonucleotide microarray tech-
nology; (b) to compare the gene expression profile with universal human 
reference RNA; and (c) to identify genes or gene products that may have 
diagnostic, prognostic, or therapeutic potential. This study is the first to suc-
cessfully perform microgenomics on formaldehyde-fixed, decalcified, and 
paraffin-embedded odontogenic tumor tissue.
MATERIAlS & METHODS
Case Selection
This study was approved by the Institutional Review Board of the University 
of North Carolina at Chapel Hill (UNC). Ameloblastoma samples were 
retrieved from the paraffin block archives of the departments of Surgical 
Pathology and Oral and Maxillofacial Pathology at UNC; the diagnosis was 
Microgenomics of 
Ameloblastoma
464  DeVilliers et al. J Dent Res 90(4) 2011
confirmed, based on the 2005 WHO Histologic Classification of 
Odontogenic Tumors (Barnes et al., 2005). Five ameloblastoma 
samples were selected (1 unicystic, 1 recurrent tumor, and 3 
solid/multicystic), all of which were originally decalcified in 
Richard Allan Scientifics’ decalcifying solution containing 
water, hydrochloric acid, EDTA, tetrasodium tartrate, potassium 
sodium, and tartrate.
laser Capture Microdissection
Serial 7-µm-thick sections were cut from each block in an 
RNAse-free lab environment for a total of 75 slides (15 from 
each block). In addition, tissue scrapes from each block of the 5 
samples were processed for the assessment of total RNA fidel-
ity, following the protocol of Optimum™ FFPE RNA Isolation 
Kit (Ambion, Inc., Austin, TX, USA) optimized for RT-PCR 
analysis. For the purposes of the present study, tissue blocks that 
were one year old or less were selected, since they provide bet-
ter fidelity than older blocks. Once the quantity and quality of 
total RNA were established, the ameloblastoma sections were 
subjected to laser capture microdissection with the AutoPix™ 
with infrared diode laser (Arcturus Engineering, Santa Clara, 
CA, USA). The cells from the basal cell layer of the ameloblas-
toma samples, which have a uniform histologic architecture, 
were microdissected. For correct identification of the cells of 
interest, H&E sections were scanned in the Aperio ScanScope™ 
system and viewing software (Vista, CA, USA). Scanned images 
were viewed simultaneously with the LCM procedure. 
Microdissected cells were captured with a CapSure™ cap 
(Arcturus Engineering), and the cells were placed in RNA 
extraction buffer. Total RNA was isolated from the microdis-
sected cells with the PicoPure RNA Isolation kit (Arcturus 
Bioscience, Santa Clara, CA, USA). The quality and yield of 
total RNA were assessed on an Agilent Bioanalyzer 2100 
(Agilent Technologies, Palo Alto, CA, USA).
RnA Amplification
The TargetAmp™ 2-Round Aminoallyl-aRNA Amplification 
Kit (Epicentre Biotechnologies, Madison, WI, USA) was used. 
This protocol is based on an improved “Eberwine” (Van Gelder 
et al., 1990) linear amplification process. In parallel with the 
laser-captured and microdissected samples, 2 additional samples 
were included in the amplification, a positive control (human 
universal RNA) and a negative control (no RNA template).
Oligonucleotide Microarray Analysis
Whole Human Genome Oligo Microarrays (G4112A) (Agilent 
Technologies Inc.) including 60-mer oligonucleotide probe 
sequences of over 41,000 human genes and transcripts were 
used. Target labeling, hybridization, washing, scanning, and 
data extraction were performed following the oligonucleotide 
microarray hybridization protocol as previously described 
(Ohyama et al., 2002). Amplified aRNA from the laser-captured 
tissue was labeled with the Cy5 dye and hybridized to the arrays 
with a Cy3-labeled Stratagene Human Universal Reference 
(Santa Clara, CA, USA). The Universal Reference labeled 
cRNA from a single labeling reaction was used in all 5 hybrid-
izations to minimize technical variance (Novoradovskaya et al., 
2004). Precautions were taken to avoid small-size aRNA hybrid-
ization to gene oligos, by removing free nucleotides as previ-
ously described (Coudry et al., 2007).
Data Analysis
The hybridized arrays were scanned at 488 nm in a G2500 Scanner 
(Agilent). A normalization factor was estimated from ratios of the 
medians. The log2 ratios for all the targets on the array were cali-
brated by the normalization factor, and log2 ratios outside the 
99.7% confidence interval were determined as significantly 
changed in the ameloblastoma cells. Cluster analysis of microarray 
data and statistical analysis were performed on the Agilent 
GeneSpring Analysis Platform™ as well as by Significance 
Analysis of Microarrays (SAM) (Larsson et al., 2005).
Validation of Protein Expression
Immunohistochemistry was performed on sections of the amelo-
blastomas used for LCM and microarray analysis as well as on 
additional samples from the Pathology laboratory archives. 
Standard protocols were used to evaluate expression and local-
ization of sonic hedgehog pathway members (SHH, Gli, Ptch, 
and SMO) (R&D Systems Inc., Minneapolis, MN, USA) and 
WNT10 (ProSci Incorporated, Poway, CA, USA). Positive and 
negative controls were included for each antibody.
RESulTS
Laser capture microdissection yielded an estimated 500 cells 
per sample (Table 1) and approximately 10-15 ng total RNA. 
The 260/280 ratio for the 5 samples was between 2.12 and 2.14. 
Anti-sense RNA generated from the ameloblastoma samples 
had an average size of 500 nucleotides. The microarray hybrid-
ization was performed with Agilent microarrays including more 
than 41,000 human genes and transcripts; the raw data have 
been submitted to the Gene Expression Omnibus (GEO) micro-
array database (accession number GPL1708). We considered 
genes based on Bonferroni’s inequality, which limits the chance 
of a false-positive result to be no more than by multiplying each 
nominal p-value by N (with a maximum of 1). Hierarchical 
cluster analysis of genes is depicted in Fig. 1. In total, 21 genes 
were highly expressed, with a two-fold increase over the refer-
ence RNA in all 5 samples (Table 2), while 41 genes were 
underexpressed (two-fold) in 4 out of 5 samples; among these 
was RAB31, a member of the RAS oncogene family (Entrez 
Gene ID 11031) T-cell acute lymphocytic leukemia 1 (Entrez 
Gene ID 6886). Variance was greater in genes expressed at low 
levels between these tumors, compared with the highly expressed 
genes between tumors.
The tumor cells consistently expressed enamel extracellular 
matrix genes, including AMELX, AMBN, ENAM, and KLK4, at 
levels similar to the reference RNA. Interestingly, MMP20 was 
not expressed at levels above background. Similarly, genes 
involved primarily in dentin formation, such as DSPP and 
DMP1, were not expressed above background.
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Table 1. Laser Capture Microdissection (LCM) and Analysis of Total RNA Obtained by LCM of Ameloblastoma Samples
(A) Sample* (B) Before LCM (C) LCM (D) RNA Expression Profile
Sample 1, 51-year-old female; 
recurrent ameloblastoma; left 
posterior mandible
Sample 2, 27-year-old female; left 
anterior mandible
Sample 3, 14-year-old female; 
posterior right mandible
Sample 4, 34-year-old female; left 
posterior maxilla
Sample 5, 17-year-old male; right 
posterior mandible
*(A) Sample description; (B, C) representative LCM images of ameloblastoma captured from H&E-stained sections; images of cells, outlined in 
yellow, marked for capture. Column C shows pure population of captured cells in the cap and section of remaining tissue after capture. (D) 
Analysis of total RNA. The 18S and 28S ribosomal RNA peaks can be observed in all samples.
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Genes that were highly expressed compared with the control 
RNA included a variety of growth factors and transcription fac-
tors. Wingless-type MMTV integration site family member 10A 
(WNT10A) was strongly expressed in our ameloblastoma sam-
ples, with a fold change of 5.1. Members of the sonic hedgehog 
(SHH) pathway also showed variable expression compared with 
reference RNA GLI1, and all 5 ameloblastomas. Patched 
(PTCH) was highly expressed, while Smoothened (SMO) was 
expressed at levels less than the reference RNA (Fig. 2, Appendix 
Table).
It has been postulated that calretinin (CALB2) is a useful 
diagnostic marker to differentiate ameloblastoma from other 
less aggressive tumors that have a similar histological appear-
ance (Altini et al., 2000). The microarray analysis we performed 
showed CALB2 to be overexpressed compared with the refer-
ence RNA in all 5 tumors. These results have been reported in 
detail elsewhere (DeVilliers et al., 2008).
DISCuSSIOn
This is the first report of the gene expression profile of amelo-
blastoma using microgenomics. This study shows that LCM of 
ameloblastoma tissue provides an accurate way to select a spe-
cific tumor cell population, thereby reducing variance intro-
duced by the inclusion of stromal tissue that confounds gene 
expression analysis. This is particularly valuable in the study of 
tumors that do not have a solid growth pattern, but rather are 
characterized by an infiltrative and cystic component that pre-
cludes the acquisition of uncontaminated tumor tissue by con-
ventional bulk tissue analysis. In our study, the wingless-type 
MMTV integration site family, member 10A, MyoD family 
inhibitor (MDFI), and BTAF1 RNA polymerase II transcription 
factor were among the overexpressed 
genes (two-fold) in 5/5 samples of ame-
loblastoma (p < 0.05). In Heikinheimo’s 
study (Heikinheimo et al., 2002) of the 
gene expression profile of fresh-frozen 
ameloblastomas (using a cDNA microar-
ray and comparing them with tooth 
germ), the oncogene FOS was the most 
overexpressed gene, followed by tumor-
necrosis-factor-receptor 1 (TNFRSF1A). 
Genes from sonic hedgehog (SHH) path-
way, TNF-receptor-associated-factor 3 
(TRAF3), deleted in colorectal carci-
noma (DCC), and transforming growth-
factor-β1 (TGFβ1), among others, were 
underexpressed. Our data agreed with 
the overexpression of cFOS and under-
expression of SHH; in contrast, we 
showed overexpression of PTCH (two-
fold), which was not the case in the 
Heikinheimo study. In 2003, Carinci 
et al. studied the genetic expression pro-
filing of 6 odontogenic tumors which 
included 3 ameloblastomas and 3 malig-
nant odontogenic tumors, comparing 
them with gingival tissue (Carinci et al., 2003). This study 
focused on the description of the gene expression of malignant 
odontogenic tumors; we did not find any of those genes signifi-
cantly expressed in our samples. Lim et al., in 2006, reported an 
oligonucleotide microarray analysis of 2 ameloblastomas com-
pared with a dentigerous cyst (Lim et al., 2006). Overexpressed 
genes postulated to play a role in the tumorigenesis of amelo-
blastoma included VAV3, EGFR, TOM1L1, FUBP1, CDK2, 
TNKS, PTHRP, SMARCA2, KLK5, and CLU. Our study found 
significant overexpression of VAV3 and FUBP1, but not the others.
WnT Expression
Identification of the strong expression of WNT10A A in all tumors 
was noteworthy. The WNT gene family in humans consists of 19 
structurally related genes that encode secreted signaling proteins. 
These proteins have been implicated in oncogenesis and in sev-
eral developmental processes, including regulation of cell fate and 
patterning during embryogenesis. Interestingly, mutation of 
WNT10A is associated with odonto-onychodermal dysplasia 
(OMIM #257980), a type of ectodermal dysplasia characterized 
by developmental abnormalities in a variety of ectodermally 
derived tissues, including missing teeth. The WNT10A gene is 
located on chromosome 2q35 and codes for a 417-amino-acid 
protein that transduces signals by binding to a receptor on the cell 
surface. High expression levels of WNT10A could play a key role 
in carcinogenesis through activation of a canonical WNT-beta-
catenin-TCF signaling pathway that is involved in cell fate deter-
mination (Molinolo et al., 2008). WNT10A is strongly expressed 
in the cell lines of promyelocytic leukemia and Burkitt’s lym-
phoma, as well as in colorectal cancer cell lines (Dorfman et al., 
2003; Dhir et al., 2008). WNT10A expression in ameloblastomas 
Figure 1. Hierarchical gene cluster analysis of ameloblastoma. Each column represents a 
tumor sample and each row a single gene. Gene expression levels are shown in descending 
order; red indicates two-fold up; green, two-fold down.
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could be mediated by tumor necrosis factor-α (TNF-α), which 
also had a high expression in our tumors. The potential induction 
of WNT10A by TNF-α and its potential role in the cytodifferentia-
tion of ameloblastoma through the activation of the WNT-β-
catenin-TCF signaling pathway deserves further study. Our results 
are supported by those of prior studies indicating an important 
role for TNF-α in ameloblastoma (Hendarmin et al., 2005; 
Kumamoto and Ooya, 2005; Sandra et al., 2005, 2006; Rizzardi 
et al., 2009).
β-catenin is involved in the Wnt signaling pathway in tumor-
igenesis by T-cell factor transcription factor (TCF); this is a 
mechanism that has been well-studied in gastric cancer 
(Kirikoshi et al., 2001). We found strong expression of TCF 
supporting activation of the canonical WNT pathway or, alterna-
tively, a loss of TCF regulation through the NKL cascade of the 
non-canonical pathway. WNT10A expression has been observed 
in the enamel knot, a critical signaling center for SHH and WNT 
pathways that are involved in tooth morphogenesis (Thesleff 
and Jernvall, 1997). The role of WNT10A in tooth development 
is not fully understood; however, its expression in the epithelial-
derived enamel knot and the loss of tooth development when it 
is mutated clearly demonstrate that it is critical for normal odon-
togenesis. WNT10A could play an important role in regulating 
the growth and morphological patterning of ameloblastoma 
tumors. Further investigation of the role of WNT10A in amelo-
blastoma tumorigenesis is warranted.
Patched (PTCH)
The SHH pathway induces carcinogenesis or promotes cell sur-
vival in cancers in multiple organs (Berman et al., 2002; Yanai 
et al., 2007), plays a critical role in tooth development (Gritli-
Linde et al., 2002), and appears to be involved in odontogenic 
tumorigenesis (Koyama et al., 2001). We identified the over-
expression of GLI1 and PTCH in all 5 ameloblastomas and 
confirmed it by immunohistochemistry (Fig. 2). Other studies 
(Heikinheimo et al., 2002; Kumamoto et al., 2004) observed the 
underexpression of sonic hedgehog (SHH) in ameloblastoma; 
our data agree with this finding. The high expression of some of 
the SHH pathway members is important, given that several 
therapeutic compounds have proven effective as antagonists of 
the SHH pathway. Cyclopamine, a plant-derived SHH pathway 
antagonist, acts at the level of SHH signaling and is effective in 
reducing the viability of cancer cells by blocking activation of 
the SHH response pathway and abnormal cell growth. Several 
cyclopamine studies have shown successful responses in breast, 
pancreatic, and gastric cancer cells, medulloblastoma, and oral 
squamous cell carcinoma cells (Nishimaki et al., 2004; 
Mukherjee et al., 2006). We suggest that the SHH pathway 
members could play an important role in the tumorigenesis of 
ameloblastomas and provide a potential therapeutic opportunity. 
Studies are under way to investigate the effect of cyclopamine 
on ameloblastoma cells.
Table 2. Expression of WNT Family of Genes and Sonic Hedgehog Pathway Members in Ameloblastoma
Expression of WNT Family of Genes in Ameloblastoma
Gene Name Annotation Average Fold Change
WISP2 WNT1 inducible signaling pathway protein 2 1.15
WISP1 WNT1 inducible signaling pathway protein 1 1.26
WISP3 WNT1 inducible signaling pathway protein 3 1.13
WISP1 WNT1 inducible signaling pathway protein 1 1.18
WNT11 Wingless-type MMTV integration site family, member 11 0.62
WNT1 Wingless-type MMTV integration site family, member 1 1.36
WNT10B Wingless-type MMTV integration site family, member 10B 1.00
WNT10A Wingless-type MMTV integration site family, member 10A 5.10
WNT11 Wingless-type MMTV integration site family, member 11 1.23
Expression of the Sonic Hedgehog Pathway Members in Ameloblastoma
Gene Name Annotation Average Fold Change
SHH Sonic hedgehog homolog (Drosophila) (SHH), mRNA 0.88
SMOX Spermine oxidase 1.13
SMOC1 SPARC-related modular calcium-binding protein 1 precursor 1.00
SMO Smoothened homolog precursor (SMO) 0.70
SMOC2 SPARC-related modular calcium-binding protein 2 precursor 0.50
PTCH Protein patched homolog 1 (PTC1) (PTC). 2.13
PTCH2 Patched homolog 2 (Drosophila) RP11-269F19.8 1.34
GLi1 Zinc finger protein GLI1 (Glioma-associated oncogene) 1.28
GLi2 Zn-finger, C2H2 type 0.98
GLI4 Zinc finger protein GLI4 (Kruppel-related zinc finger protein 4) 0.56
GLIPR1 Glioma pathogenesis-related protein 1 precursor 0.54
GLI3 GLI-Kruppel family member GLI3 0.43
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Genes that were underexpressed (two-fold down) in our 
study included RAB31, a member of the RAS oncogen family 
and a GTPase-mediated signal transduction; T-cell acute lym-
phocytic leukemia 1, important in cell differentiation, cell pro-
liferation, and regulation of transcription and DNA binding; and 
ST13 (suppression of tumorigenicity 13, colon carcinoma), 
which functions in protein binding and bridging.
In this paper, we described how amplified aRNA generated 
from ameloblastoma cells harvested by laser capture microdissec-
tion and microarray analysis provided a highly efficient approach 
for establishing gene expression profiles for specific tumor cell 
populations. Several of the genes and their proteins that were 
highly expressed in ameloblastoma cells have good potential as 
therapeutic targets, including the SHH pathway member PTCH. 
The protein WNT10A was highly expressed in our ameloblas-
toma samples, and it may be mediated by tumor necrosis factor-α 
(TNF-α), which was also highly expressed. Presently, radical 
surgery remains the therapy of choice for ameloblastomas. It is 
critical to identify potential molecular pathways that provide an 
opportunity for novel therapies directed at reducing the size of 
these tumors prior to surgical intervention and potentially achiev-
ing a lower incidence of recurrence and metastasis.
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Figure 2. Confirmation of expression of WNT10a, PTCH, and Gli1 in ameloblastoma by 
immunohistochemistry. (A) Reactivity for WNT10a at 10x; (B) reactivity for WNT10a at 20x; 
(C) reactivity for PTCH at 10x; (D) reactivity for Gli1 at 20x; and (E) negative control at 10x.
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